Conversations with the Academy webinar:

May 12, 2022

COVID-19 has fundamentally altered the drug development landscape in ways that are both transformational and far-reaching. From the integration of powerful technologies to assist with the discovery and development of promising new drug candidates, to the adoption of novel, decentralized clinical trial designs, which reduce the burden on patients participating in clinical studies, the drug development enterprise has met the challenge of COVID-19, and is embracing new operational and business models to maximize productivity and ROI going forward.

In this webinar, we will examine the changing global landscape for pharmaceutical R&D, focusing specifically on COVID-19 and its influence on R&D and business strategies, as well as regulatory policies pertaining to the development and approval of important new pharmaceutical therapies.

Learning Objectives

1. Assess the current economic and regulatory factors that affect pharmaceutical R&D

2. Review the drug development community’s response to the COVID-19 pandemic, leading to the development and approval of several highly effective vaccines and therapeutics

3. Examine the longer-term impact of COVID-19 on R&D strategy, business models, and regulatory policy